This prospective multicenter study aims at exploring the impact of infections on intra-hospital and 3-month changes in the frailty profile of older inpatients.
To understand the complex pathways under the relationship between infections and frailty, this study will evaluate infection-related clinical and biochemical markers of systemic inflammation and genetics/epigenetics markers at ward admission.
The interplay between clinical, functional, and genetics/epigenetics factors will be evaluated in a subgroup of patients by testing whether 3-month changes in frailty concur with changes in the genomic DNA markers. This study will help characterize the pathophysiological mechanisms of frailty and identify at-risk conditions that may accelerate its course.

开始日期2024-05-20

申办/合作机构

Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuel

NCT05592171 / RecruitingN/AIIT

A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Occlusafe® Assisted Microwave Alone or in Combination With DEB-TACE Compared to Microwave in Combination With DEB-TACE in the Treatment of Intermediate Size HCC

The goal of this Interventional Study is to compare the efficacy profile and safety of three treatments in patients with HCC nodule.
Patients will be randomly divided in three arms:
Occlusafe assisted MWA+ DEB-TACE
Occlusafe assisted MWA
MWA+ DEB-TACE
The primary objectives are evaluate the safety of the three treatments; evaluate the effectiveness of treatments one month after the procedure (defined as complete ablation of macroscopic tumor at one month of follow-up), verifying the possible superiority of arm 1 and arm 2 compared to arm 3.
The secondary objective is: time to local disease recurrence.

开始日期2022-10-17

申办/合作机构

University of Pisa

[+3]

NCT04676321 / CompletedN/A

Key Performance Indicators for the Assessment of Diagnostic and Therapeutic Pathway of NSCLC Patients: a Multicenter Study (KIND NSCLC)

This is a multicenter, observational study involving a retrospective collection of data. A total of potential 16 key performance indicators (KPIs) had been developed from a panel of experts (clinicians, IT experts, etc..) to investigate the appropriateness of care in NSCLC patients, with a special focus on the use of immunotherapy. The eligible population and data will be gathered retrospectively using an algorithm. Administrative databases will be used as unique resource: to identify target population and to collect patient's data with which measure KPIs.

开始日期2020-10-01

申办/合作机构

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL

[+2]

100 项与 Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuel 相关的临床结果

登录后查看更多信息

0 项与 Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuel 相关的专利（医药）

登录后查看更多信息

201

项与 Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuel 相关的文献（医药）

2024-01-02·International Journal of Management Science and Engineering Management

System design of outpatient chemotherapy oncology departments through simulation and design of experiments

作者: Pluchino, A. ; Corsini, R. R. ; Parrinello, V. ; Costa, A. ; Fichera, S.

2024-01-01·The American Journal of Cardiology

Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Atrial Functional Mitral Regurgitation from the GIOTTO Registry

Article

作者: Giordano, Arturo ; Bedogni, Francesco ; Tamburino, Corrado ; Giannini, Cristina ; Giulia, Lorenzoni ; Godino, Cosmo ; Dario, Gregori ; Petroni, Anna Sonia ; Rubbio, Antonio Popolo ; Villa, Emmanuel ; Monteforte, Ida ; Adamo, Marianna ; Mongiardo, Annalisa ; Montorfano, Matteo ; Masiero, Giulia ; Giuseppe, Tarantini ; Montonati, Carolina ; Grasso, Carmelo ; Bartorelli, Antonio Luca ; Denti, Paolo ; De Felice, Francesco

Atrial functional mitral regurgitation (aFMR) has a peculiar pathophysiology that may have distinctive outcomes. We investigated the impact of transcatheter edge-to-edge repair in aFMR compared with other FMR etiologies. The GIOTTO (GIse registry Of Transcatheter treatment of MR) is a multicenter, prospective study enrolling patients with symptomatic MR treated with MitraClip up to 2020. We categorized patients with FMR as aFMR, ischemic FMR (iFMR), and nonischemic ventricular FMR (niFMR). The clinical end points were defined according to the Mitral Valve Academic Research Consortium. Of 1,153 patients, 6% had aFMR, 47% iFMR, and 47% niFMR. Patients with aFMR were older, mostly women, and had a higher atrial fibrillation rate. They had better left ventricular ejection fraction and smaller left ventricular volumes, with no difference in mitral effective regurgitant orifice area. The acute device and procedural success rates were similar among the groups. At the longest available follow-up (median 478 days, interquartile range 91 to 741 days), the rate of MR ≥2+ was similar among the groups. Patients with aFMR had a lower rate of cardiovascular death and heart failure than patients with iFMR (hazard ratio [HR] 0.43, p = 0.02) and niFMR (HR 0.45, p = 0.03). The aFMR etiology remained independently associated with the composite outcome, together with postprocedural MR ≤1+ (HR 0.63, p <0.01) and peripheral arteriopathy (HR 1.82, p = 0.003). The results of this GIOTTO subanalysis suggested that aFMR is less prevalent and associated with better outcomes compared with other causes of FMR treated by transcatheter edge-to-edge repair. Postprocedural MR >1+, peripheral vasculopathy, non-aFMR were independent predictors of worse outcomes.

2023-11-01·International Journal of Cardiology

2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry

Article

作者: Crimi, Gabriele ; Guerin, Patrice ; Fiorelli, Francesca ; Tarantini, Giuseppe ; Giannini, Cristina ; Munafò, Andrea Raffaele ; Oreglia, Jacopo A ; Adamo, Marianna ; Marcelli, Chiara ; Maffeo, Diego ; Arzamendi, Dabit ; Ooms, J F ; Potena, Luciano ; Fürholz, Monika ; Raineri, Claudia ; Estévez-Loureiro, Rodrigo ; Godino, Cosmo ; Van Mieghem, Nicolas M ; Peregrina, Estefanìa Fernàndez ; Pezzola, Elisa ; Le Ruz, Robin ; Taramasso, Maurizio ; Agricola, Eustachio ; Bettari, Luca ; Petronio, A Sonia ; Fam, Neil P ; Montalto, Claudio ; Chizzola, Giuliano ; Maisano, Francesco ; Praz, Fabien ; Vitrella, Giancarlo ; Asgar, Anita ; Compagnone, Miriam ; Gutierrez, Lola ; Saia, Francesco ; Ho, Edwin C ; Tamburino, Corrado ; Pascual, Isaac ; Fraccaro, Chiara ; Colombo, Antonio ; Scotti, Andrea ; Hernàndez, Antonio Portolés ; Metra, Marco ; Rubbio, Antonio Popolo ; Grasso, Carmelo ; Margonato, Alberto

BACKGROUNDIn the first report from the MitraBridge registry, MitraClip as a bridge to heart transplantation (HTx) proved to be at 1-year an effective treatment strategy for 119 patients with advanced heart failure (HF) who were potential candidates for HTx. We aimed to determine if benefits of MitraClip procedure as a bridge-to-transplant persist up to 2-years.METHODSBy the end of the enrollment period, a total of 153 advanced HF patients (median age 59 years, left ventricular ejection fraction 26.9 ± 7.7%) with significant secondary mitral regurgitation, who were potential candidates for HTx and were treated with MitraClip as a bridge-to-transplant strategy, were included in the MitraBridge registry. The primary endpoint was the 2-year composite adverse events rate of all-cause death, first hospitalization for HF, urgent HTx or LVAD implantation.RESULTSProcedural success was achieved in 89.5% of cases. Thirty-day mortality was 0%. At 2-year, Kaplan-Meier estimates of freedom from primary endpoint was 47%. Through 24 months, the annualized rate of HF rehospitalization per patient-year was 44%. After an overall median follow-up time of 26 (9-52) months, elective HTx was successfully performed in 30 cases (21%), 19 patients (13.5%) maintained or obtained the eligibility for transplant, and 32 patients (22.5%) no longer had an indication for HTx because of significant clinical improvement.CONCLUSIONSAfter 2-years of follow-up, the use of MitraClip as a bridge-to-transplant was confirmed as an effective strategy, allowing elective HTx or eligibility for transplant in one third of patients, and no more need for transplantation in 22.5% of cases.

100 项与 Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuel 相关的药物交易

登录后查看更多信息

100 项与 Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuel 相关的转化医学

登录后查看更多信息